DeepMed Research

Adebrelimab

Generic Name: Adebrelimab

Drug Type: Biotech

CAS Number: 2247114-85-6

Unique Ingredient Identifier: 1XBY50W1OX

Background: Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).

Indication: 用于与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。

Clinical Trials

The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Clinical IVb Stage Oral Squamous Cell Carcinomas Patients

Interventions: Drug: Adebrelimab

First Posted Date: 2024-02-26

Last Posted Date: 2024-02-26

Lead Sponsor: Hospital of Stomatology, Wuhan University

Target Recruit Count: 35

Registration Number: NCT06277791

Locations: 🇨🇳
School of Stomatology Wuhan University, Hubei, Wuhan, China

A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer

Not yet recruiting

Conditions: SCLC,Extensive Stage

First Posted Date: 2024-02-20

Last Posted Date: 2024-02-20

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 288

Registration Number: NCT06267170

The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma

Phase 2

Recruiting

Conditions: Rectal Adenocarcinoma

Interventions: Drug: Adebrelimab
Drug: Oxaliplatin
Drug: Capecitabine
Radiation: Short-course Radiation
Procedure: Biopsy

First Posted Date: 2024-02-20

Last Posted Date: 2024-02-20

Lead Sponsor: Sir Run Run Shaw Hospital

Target Recruit Count: 30

Registration Number: NCT06266832

Locations: 🇨🇳
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Radiation: Stereotactic body radiotherapy
Drug: Adebrelimab
Drug: Lenvatinib

First Posted Date: 2024-02-15

Last Posted Date: 2024-03-12

Lead Sponsor: Mian XI

Target Recruit Count: 60

Registration Number: NCT06261125

Locations: 🇨🇳
Mian Xi, Guangzhou, Guangdong, China

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Phase 2

Not yet recruiting

Conditions: Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer
Female Breast Cancer Patients
HRD Positive Advanced Breast Cancer

Interventions: Drug: Adebrelimab plus Fluzoparib

First Posted Date: 2024-02-12

Last Posted Date: 2024-02-12

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 40

Registration Number: NCT06254066

Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)

Phase 2

Recruiting

Conditions: Prostate Cancer Metastatic
Castration-resistant Prostate Cancer

Interventions: Radiation: Stereotactic body radiotherapy
Drug: Adebrelimab

First Posted Date: 2024-02-09

Last Posted Date: 2024-02-20

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT06251492

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳
Fudan University Shanghai Cancer Center Xiamen Branch., Xiamen, Fujian, China
🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer

Phase 2

Active, not recruiting

Conditions: Locally Advanced Cervical Cancer

Interventions: Biological: SHR-1316
Drug: Cisplatin Injection/Carboplatin Injection
Radiation: External Beam Radiotherapy (EBRT)/Brachytherapy
Drug: Paclitaxel Injection

First Posted Date: 2024-02-01

Last Posted Date: 2025-03-25

Lead Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd

Target Recruit Count: 56

Registration Number: NCT06237257

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

Phase 2

Not yet recruiting

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: Adebrelimab
Radiation: Radiation Therapy
Drug: etoposide, carboplatin(EC)

First Posted Date: 2024-02-01

Last Posted Date: 2024-02-01

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 48

Registration Number: NCT06236997

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Tongji Hospital, Tongji Medical College，Huazhong University of Science and Technology, Wuhan, Hubei, China

Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer

Phase 2

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Adebrelimab + Cetuximab+ Chemotherapy

First Posted Date: 2024-01-30

Last Posted Date: 2024-01-30

Lead Sponsor: The First Affiliated Hospital of Zhengzhou University

Target Recruit Count: 36

Registration Number: NCT06231017

Locations: 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Cancer
Triple Negative Breast Cancer

Interventions: Drug: Adebrelimab
Drug: Cyclophosphamide (tablet)
Drug: Vinorelbine
Drug: Capecitabine

First Posted Date: 2024-01-29

Last Posted Date: 2024-01-29

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 182

Registration Number: NCT06229067

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy